Drug Information

Drug General Information
Drug ID
D0XS9E
Former ID
DNC006597
Drug Name
(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528209]
Structure
Download
2D MOL

3D MOL
Formula
C17H12N2O2
Canonical SMILES
C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)O
InChI
1S/C17H12N2O2/c20-12-5-6-14-11(7-12)9-16(19-14)17(21)15-8-10-3-1-2-4-13(10)18-15/h1-9,18-20H
InChIKey
AALNCHNFTKRFEL-UHFFFAOYSA-N
PubChem Compound ID
5330535
Target and Pathway
Target(s) Beta platelet-derived growth factor receptor Target Info Inhibitor [528209]
FL cytokine receptor Target Info Inhibitor [528209]
Alpha platelet-derived growth factor receptor Target Info Inhibitor [528209]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Calcium signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Focal adhesion
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
Pathways in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancerhsa04060:Cytokine-cytokine receptor interaction
Hematopoietic cell lineage
Transcriptional misregulation in cancer
Acute myeloid leukemia
Central carbon metabolism in cancerhsa04010:MAPK signaling pathway
Endocytosis
Choline metabolism in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Angiogenesis
PDGF signaling pathwayP00005:Angiogenesis
PDGF signaling pathway
Pathway Interaction Database Signaling events mediated by PTP1B
Beta3 integrin cell surface interactions
S1P3 pathway
Nectin adhesion pathway
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PDGFR-beta signaling pathway
Validated targets of C-MYC transcriptional repression
PDGF receptor signaling networkatf2_pathway:ATF-2 transcription factor network
PDGFR-alpha signaling pathway
PDGF receptor signaling network
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascadeR-HSA-1257604:PIP3 activates AKT signaling
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Osteoblast Signaling
Focal Adhesion
PIP3 activates AKT signaling
PDGF Pathway
Signaling Pathways in Glioblastoma
Signaling by PDGFWP51:Regulation of Actin Cytoskeleton
Hair Follicle Development: Organogenesis (Part 2 of 3)
Cardiac Progenitor Differentiation
Integrated Pancreatic Cancer Pathway
Allograft Rejection
Signaling by PDGF
Angiogenesis
References
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Ref 528209J Med Chem. 2006 Jun 1;49(11):3101-15.Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.